Celcuity (NASDAQ:CELC) Releases Earnings Results, Misses Estimates By $0.28 EPS

Celcuity (NASDAQ:CELC) announced its earnings results on Thursday. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28), Zacks reports. The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $4.42 million.

Here are the key takeaways from Celcuity’s conference call:

• REVTORPYK was FDA-approved for HR-positive, HER2-negative advanced breast cancer without detected PIK3CA mutations, and both its doublet and triplet regimens received preferred Category 1 recommendations in the NCCN guidelines.
• In the PIK3CA-mutant VIKTORIA-1 cohort, gedatolisib-based regimens significantly improved median progression-free survival to approximately 11 months versus 5.6 months for alpelisib plus fulvestrant, while treatment discontinuation due to adverse events was lower for gedatolisib. Celcuity plans to submit an sNDA in the third quarter of 2026.
• Celcuity remains confident that commercial shipments will begin in late Q3 2026. The company has completed its commercial infrastructure, deployed 88 oncology sales specialists, begun an expanded-access program, and estimates a U.S. addressable market exceeding $6 billion annually.
• The VIKTORIA-2 first-line breast cancer program has been expanded to include endocrine-sensitive patients, potentially broadening gedatolisib’s use across most newly diagnosed advanced HR-positive, HER2-negative patients. Celcuity also expects to provide additional prostate cancer data in Q4 2026.
• Second-quarter net loss widened to $78.9 million from $45.3 million year over year, while selling, general and administrative expenses rose sharply due to launch preparation. The company ended June with $754 million in cash and investments and expects funding into 2029, helped by a $575 million convertible-note offering.

Celcuity Stock Performance

Shares of CELC stock traded up $5.40 during trading hours on Friday, reaching $92.00. 1,333,561 shares of the company’s stock were exchanged, compared to its average volume of 1,114,674. The company has a market cap of $4.49 billion, a P/E ratio of -23.59 and a beta of 0.20. The company’s 50 day moving average is $93.81 and its two-hundred day moving average is $108.56. Celcuity has a 1 year low of $44.42 and a 1 year high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31.

Key Headlines Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $155 price target, implying substantial upside from the recent $92 share price. The endorsement reinforces bullish sentiment following Celcuity’s regulatory and commercial progress. Benzinga analyst rating report
• Positive Sentiment: An analyst report maintained a Buy view, citing REVTORPYK/gedatolisib’s FDA approval and rapid NCCN Category 1 inclusion as factors that reduce clinical and adoption risk. Strong VIKTORIA-1 results, including improved efficacy and tolerability, could support rapid physician uptake and a potential blockbuster franchise. Celcuity also reported approximately $754 million in cash, providing funding visibility through 2029 despite elevated launch spending. Celcuity: REVTORPYK Is Now A Commercial Story
• Neutral Sentiment: Stifel Nicolaus maintained a Buy rating but reduced its price target from $175 to $150, while Needham kept a Buy rating and lowered its target from $157 to $140. Both firms remain bullish, but the cuts indicate more cautious near-term assumptions. Benzinga analyst rating reports
• Negative Sentiment: Celcuity’s second-quarter results highlighted commercialization-related financial pressure. The company reported a $1.44 per-share loss, wider than the $1.16 consensus loss, and revenue of only $0.09 million versus the $4.42 million estimate. The results and increased launch-related SG&A prompted analysts to reduce forecasts, although the company’s cash balance provides a substantial operating runway. Celcuity second-quarter 2026 results

Institutional Trading of Celcuity

A number of institutional investors have recently modified their holdings of CELC. Creative Planning purchased a new position in Celcuity in the second quarter worth $177,000. Rhumbline Advisers boosted its position in shares of Celcuity by 1.2% during the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after purchasing an additional 503 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Celcuity during the 2nd quarter worth $169,000. Quantinno Capital Management LP grew its stake in shares of Celcuity by 20.7% during the 2nd quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock worth $3,245,000 after purchasing an additional 41,756 shares during the period. Finally, Paloma Partners Management Co grew its stake in shares of Celcuity by 285.8% during the 2nd quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock worth $1,097,000 after purchasing an additional 60,849 shares during the period. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CELC has been the subject of a number of research reports. Needham & Company LLC reduced their target price on shares of Celcuity from $157.00 to $140.00 and set a “buy” rating for the company in a report on Friday. Stifel Nicolaus lowered their price target on Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a report on Friday. Craig Hallum restated a “buy” rating and issued a $178.00 price target on shares of Celcuity in a research report on Wednesday, July 15th. Leerink Partners set a $155.00 price objective on Celcuity in a research note on Tuesday, June 2nd. Finally, Citigroup reaffirmed an “outperform” rating on shares of Celcuity in a research report on Wednesday, July 15th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Celcuity has a consensus rating of “Moderate Buy” and a consensus price target of $153.64.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.